Department of Pediatrics, Copenhagen Diabetes Research Center (CPH-DIRECT), Copenhagen University Hospital, Copenhagen, Denmark.
Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Pediatr Diabetes. 2018 Jun;19(4):733-740. doi: 10.1111/pedi.12652. Epub 2018 Feb 26.
Dermatological complications in children and adolescents that are related to continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) have not been well-characterized. This study examined the prevalence and characteristics of different types of dermatological complications.
Online questionnaires regarding dermatological complications related to CSII and/or CGM were returned from a total of 144 children and adolescents, aged 2 to 20 years. Both previous and current skin problems were reported along with their clinical characteristics. Descriptive statistics, χ tests, and multivariate analyses were used to evaluate the data.
Of 143 patients using CSII, 90% had previous and 63% reported current dermatological complications. Non-specific eczema was most frequently reported and was currently present in 25.7% of the patients. These results were independent of age and current CGM use. Among the 76 patients using CGM, 46% reported current dermatological complications. A history of atopy was associated with dermatological complications in individuals using CSII, but not CGM. The patients rated CGM-related dermal issues as significantly worse than those associated with CSII (P < .05).
Dermatological complications can be a serious problem in treating pediatric and adolescent patients of all ages with CSII and/or CGM. Only a few clinical characteristics associated with these complications were identified in this study, highlighting the need for prospective studies that might lead to improvements in the prevention and treatment of dermatological problems.
与持续皮下胰岛素输注（CSII）和连续血糖监测（CGM）相关的儿童和青少年皮肤科并发症尚未得到很好的描述。本研究检查了不同类型皮肤科并发症的患病率和特征。
通过在线问卷，共收到了 144 名年龄在 2 至 20 岁的儿童和青少年关于 CSII 和/或 CGM 相关皮肤科并发症的反馈。报告了之前和当前的皮肤问题及其临床特征。使用描述性统计、卡方检验和多变量分析来评估数据。
在使用 CSII 的 143 名患者中，90%有过既往皮肤科并发症，63%报告了当前的皮肤科并发症。非特异性湿疹最常被报告，目前有 25.7%的患者存在。这些结果与年龄和当前 CGM 使用无关。在使用 CGM 的 76 名患者中，46%报告了当前的皮肤科并发症。在使用 CSII 的患者中，特应性病史与皮肤科并发症相关，但在使用 CGM 的患者中则不然。患者认为 CGM 相关的皮肤问题比 CSII 相关的皮肤问题严重得多（P <.05）。
皮肤科并发症可能是治疗所有年龄段儿童和青少年使用 CSII 和/或 CGM 的严重问题。本研究仅确定了与这些并发症相关的少数临床特征，这突出了需要进行前瞻性研究，以改善皮肤科问题的预防和治疗。
